Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Top dividend stocks like Johnson & Johnson, Coca-Cola, and McDonald's offer $758 passive income on $30K investment.

Market News
20 May 2026
24/7 Wall Street
View Source
Bullish
pluang ai news

Dividend Aristocrats such as Johnson & Johnson, Coca-Cola, and McDonald's provide reliable and growing passive income through decades of consistent dividend increases. Investing $10,000 in each of these stocks can generate a combined annual passive income of $758, with yields around 2.5%. These companies benefit from durable business models and strong cash flows, allowing them to raise dividends faster than inflation. This steady income plus liquidity offers advantages over real estate or private credit investments.

More News (JNJ)

Johnson & Johnson offers more stable returns and dividend growth than Pfizer despite Pfizer's higher yield.

Johnson & Johnson offers more stable returns and dividend growth than Pfizer despite Pfizer's higher yield.

Johnson & Johnson (JNJ) is seen as having a superior return and risk profile compared to Pfizer (PFE), mainly due to its consistent dividend growth over 63 years, lower payout ratio, ongoing share buybacks, and stable inventory levels. While Pfizer o...

Company Fundamentals
Bullish
5 hours ago
Vanguard's VYM ETF offers steady, growing income across 540 stocks, ideal for retirees seeking low-maintenance dividends.

Vanguard's VYM ETF offers steady, growing income across 540 stocks, ideal for retirees seeking low-maintenance dividends.

Vanguard High Dividend Yield ETF (VYM) provides retirees with a stable income stream by distributing about 2.9% yield across roughly 540 stocks, minimizing concentration risk. Its portfolio includes large-cap dividend payers like JPMorgan Chase and P...

Market News
Neutral
1 day ago
Johnson & Johnson stock rises 2.58% with a strong buy rating and $252 price target amid oncology growth.

Johnson & Johnson stock rises 2.58% with a strong buy rating and $252 price target amid oncology growth.

Johnson & Johnson shares increased 2.58% recently, supported by strong oncology sales and a solid Q1 earnings beat with $24.06 billion revenue and $2.70 EPS. The company raised its full-year revenue and EPS guidance, driven by growth in drugs like DA...

Analyst Insights
Bullish
1 day ago
A retiree lost $2,400 in tax savings due to an overlooked wash-sale rule triggered by automatic dividend reinvestment.

A retiree lost $2,400 in tax savings due to an overlooked wash-sale rule triggered by automatic dividend reinvestment.

A 66-year-old retiree in Pennsylvania aimed to generate $55,000 annually from a $1.1 million portfolio but lost $2,400 in tax savings because her IRA automatically reinvested dividends shortly after she sold shares at a loss. This triggered the IRS w...

Market News
Bearish
2 days ago
Early data show JNJ-1900 (NBTXR3) boosts response rates in stage 3 inoperable lung cancer patients.

Early data show JNJ-1900 (NBTXR3) boosts response rates in stage 3 inoperable lung cancer patients.

Nanobiotix and Johnson & Johnson presented early Phase 2 trial data for JNJ-1900 (NBTXR3), a novel nanoradioenhancer, in stage 3 inoperable non-small cell lung cancer (NSCLC). The treatment, combined with chemoradiotherapy and durvalumab, showed an o...

Market News
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App